DrMedHealth logo

DrMedHealth Review

Appears to have shut down
6.2

DrMedHealth is closed and is not taking new patients. It charged from $199 a month.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

DrMedHealth is no longer taking new patients. This program appears to have shut down, so we're not linking to it. Here are the top-rated GLP-1 providers we recommend instead.

Last published price before it closed: $199/mo. No longer offered.

See our top-rated GLP-1 providers →
Compare top-rated alternatives ↓

DrMedHealth sold compounded semaglutide and tirzepatide by telehealth. It no longer does. In October 2026 its domain was an AI health-assistant directory, every former treatment page served that directory, and its legal page called the GLP-1 program “our former telehealth service”.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

Vetted alternatives to DrMedHealth

9.3/ 10
Verified partner

Embody

Best for: a flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

★★★★★9.3/10

Editorial score · methodology

$79/mo
CompoundedSemaglutideTirzepatideGlutathioneNAD+
Get StartedRead full Embody review →
9.1/ 10
Verified partner

Collective

Best for: flat any-dose pricing, if you can absorb a $199 annual membership on top

★★★★★9.1/10

Editorial score · methodology

$59/mo+ membership
CompoundedSemaglutideTirzepatide
Get StartedRead full Collective review →
7.4/ 10
Verified partner

AgelessRx

Best for: microdosed compounded GLP-1s from a longevity clinic, or brand Wegovy at manufacturer pricing plus monitoring

★★★★☆7.4/10

Editorial score · methodology

$99/moprepaid
CompoundedSemaglutideTirzepatideGHK-CuGlutathione
Get StartedRead full AgelessRx review →
DrMedHealth logo
6.2 / 10
Our editorial rating

DrMedHealth at a glance

Status
Closed: not taking new patients
Type
GLP-1 telehealth provider
Medications
Compounded semaglutide, Compounded tirzepatide
Last published price
$199/mo
What it included
Medication · Consult · Shipping
FDA status
1 FDA warning letter (details below)

How DrMedHealth scores

DrMedHealth has closed. These scores describe what it published when we last checked it, before it stopped taking patients.

Six columns, each one computed from something DrMedHealth published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where a seller keeps something back, such as its price or its pharmacy, the score reflects it. Every seller we review goes through the same six columns.

Value25%

3.0/10

The listed figure is not a comparable monthly price for a named GLP-1 (it may be a membership fee, an insured copay, a per-vial rate or a starting-dose price), so Value is capped rather than scored against other sellers.

Effectiveness25%

10.0/10

Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).

User Experience15%

8.0/10

A price is shown before the questionnaire starts.

Trust & Safety15%

3.5/10

The FDA has issued it a warning letter. No pharmacy is named for its prescriptions. It shows a price before asking for health information.

Accessibility10%

5.0/10

No state list is available to check, so this is held at the midpoint rather than scored on reach.

Support10%

7.0/10

The price covers the medication, clinician visits and shipping.

6weighted dimensions
734sellers compared
Everychecked against the seller's own site
Value 25%Effectiveness 25%User Experience 15%Trust & Safety 15%Accessibility 10%Support 10%

A seller that shows no price until after the medical intake loses points on User Experience and Trust & Safety, and its review says so. How we score →

What we checked on DrMedHealth

Last checked August 2026
  • Checked the listed price across 2 dose or plan tiers
  • Checked what the monthly price covers, and what it leaves out
  • Checked FDA warning letters for DrMedHealth

Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below.

Medications DrMedHealth listed

DrMedHealth listed compounded semaglutide and compounded tirzepatide. Each one has its own guide: how it works, the dosing schedule, the side effects that show up in practice, and what the trials measured.

Prices it published before closing

Prices re-verified

startingCompounded
$199/mo
semaglutide
startingCompounded
$299/mo
tirzepatide

In its favor

  • Showed its price before the medical questionnaire, so you could compare it without handing over health information
  • The monthly price included the medication, clinician visits and shipping

Against it

  • The FDA has issued DrMedHealth a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality

DrMedHealth is no longer taking new patients. What follows describes the program as it last ran, for anyone comparing it with a seller that is still open.

What DrMedHealth charged

DrMedHealth charged $199/month.

  • Compounded semaglutide: $199/month
  • Compounded tirzepatide: $299/month

Belle Health, at about $199/month, is the closest like-for-like alternative we review.

What DrMedHealth dispensed

DrMedHealth prescribed semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.

Safety and disclosure

DrMedHealth told buyers its price before the medical questionnaire. The FDA has issued DrMedHealth a warning letter, summarized at the top of this page. A letter flags a problem rather than ruling a seller out, so read what it says before deciding what it means for you. How we weigh oversight, disclosure and price is set out in our scoring methodology.

Our read

DrMedHealth is no longer taking new patients, so the choice is among the sellers that are still open. Whatever you decide, read the warning letter summarized at the top of this page first, and raise it with the clinician who would prescribe for you.

The Bottom Line

DrMedHealth is closed and is not taking new patients. It charged from $199 a month.

Score: 6.2/10Best for: seeing what it charges before you answer any medical questionsFrom: $199/mo

Where DrMedHealth is the wrong choice

No seller suits every reader, and pretending otherwise is the easiest way to sell one. On these three counts, another seller does better.

  • If you need the FDA-approved pen rather than a compounded vial, consider WellMedRx.
  • If the standing monthly cost is what decides it, consider Collective (from $59/mo + membership).
  • If you want a human checking in, not just a prescription, consider Eden.

If none of these fits, our guide to alternatives to DrMedHealth sets more sellers in the same category beside DrMedHealth on price, states and what the price includes.

Frequently Asked Questions

DrMedHealth sold compounded semaglutide and tirzepatide by telehealth. It no longer does. In October 2026 its domain was an AI health-assistant directory, every former treatment page served that directory, and its legal page called the GLP-1 program “our former telehealth service”. We rate it 6.2/10 overall.
DrMedHealth is no longer taking new patients: the program appears to have shut down, so there is nothing to sign up for. The alternatives listed on this page are still open.
Before it closed, DrMedHealth listed prices from $199 a month. The pricing table above shows every price it published.
DrMedHealth is no longer taking new patients in any state.
DrMedHealth listed compounded semaglutide and compounded tirzepatide.
DrMedHealth listed compounded GLP-1s only. A licensed compounding pharmacy prepares them: same active ingredient as the brand drug, lower cash price, and no FDA approval of the finished product.
DrMedHealth said the price covered medication, the clinician visit and shipping.
You can't: DrMedHealth is no longer taking new patients. The alternatives listed on this page are still open.
DrMedHealth is no longer taking new patients, so there is nothing to buy. The FDA warning letter it received is summarized at the top of this review.
Other sellers we cover include Belle Health, HumeCare+, and Gala. Which one fits depends on the medication, the monthly price you can sustain and whether it ships to your state, so compare those three facts before you switch.

Glossary

The words sellers use, defined. Tap any term.

Regulatory notice

DrMedHealth has an FDA warning letter on record, dated June 8, 2026

This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.

Read the full letter →

Sources

Cited across this DrMedHealth review: primary regulatory filings, and peer-reviewed studies.

Sources & methodology — as of August 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  5. 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  8. 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  9. 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  10. 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  11. 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
  12. 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.